Bioequivalency, Business Development and Generic Drugs

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Bioequivalency

Business Development

Generic Drugs

TLC Provides Corporate Update at Investor Conference – Dec 18, 2020

The Pharma Data

DECEMBER 17, 2020

George Yeh, President of TLC, commenced the conference and welcomed the company’s new Chief Business Officer, Mr. Tom Bliss. With experiences attained in licensing and business development functions from Amgen, Baxter and Johnson & Johnson, Mr. Bliss introduced himself in Mandarin Chinese.

Clinical Trials

Clinical Trials Clinical Trials Trials Containment

Using FDA Product Specific Guidances (PSGs) as a Trigger for Generic Drug Development

Drug Patent Watch

DECEMBER 11, 2024

Generic drugs play a crucial role in providing affordable healthcare options to millions of patients worldwide. One of the key tools that generic drug manufacturers rely on to navigate the complex regulatory environment is the FDA’s Product Specific Guidances (PSGs). ” – Dr.

Generic Drugs

Generic Drugs Production Development Bioequivalency

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Clinical Research Informer

TLC Provides Corporate Update at Investor Conference – Dec 18, 2020

Using FDA Product Specific Guidances (PSGs) as a Trigger for Generic Drug Development

Webinars

Stay Connected